ERBB2 and breast cancer: Considering different national conditions and medical environments, this study conducted the model-based cost-effectiveness analyses of margetuximab over trastuzumab, each with chemotherapy, for pretreated ERBB2-positive advanced breast cancer population from the US and the Chinese perspective, leveraging clinical and outcomes data in the SOPHIA trial.